retatrutide phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished retatrutide peptide | peptidesskin

Ozempic (semaglutide) is primarily prescribed for the management of type 2 diabetes

L.et al (1996)

Regarding weight loss, individuals treated with tirzepatide lost an average of 10.7 kg, while the dulaglutide group lost only about 0.5 kg

The model of the open state conformation was based on the cryo-EM structure of GLP-1GLP-1RGs (PDB: 5VAI) and the Fab7F38ECD complex of the Fab7F38GLP-1R crystal structure presented here, which were superimposed on their ECDs using PyMOL

Consistency is key to maintaining a steady level of the medication in your bloodstream, which helps minimize side effects and maximize the appetite-suppression benefits